Ardelyx (ARDX) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed Ardelyx (ARDX) over the past year, gaining 71.2% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -85.7% for HELP. Ardelyx is the larger company by market cap ($837.8 million vs $813.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | HELP |
|---|---|---|
| Share price | $3.25 | $11.13 |
| Market cap | $837.82M | $813.16M |
| 1-day change | -0.76% | +3.82% |
| YTD return | -43.91% | +31.05% |
| 1-year return | -35.38% | +71.25% |
| 5-year return | +202.78% | -85.68% |
| Forward P/E | 11.17 | — |
| EPS (TTM) | $-0.23 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $15.15 |
| 52-week low | $3.18 | $3.76 |
| Distance from 52-week high | -61.37% | -26.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +297.53% | +257.86% |
| Average volume | 4.17M | 1.77M |
| Shares outstanding | 258.19M | 73.06M |
| Employees | 489 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed ARDX by 106.6 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ARDX vs HELP FAQ
Which is bigger, Ardelyx or Helus Pharma?
Ardelyx (ARDX) is larger, with a market capitalization of $837.82M compared with $813.16M for Helus Pharma (HELP).
Which stock has performed better over the past year, ARDX or HELP?
HELP returned +71.25% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.